Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Fibrosing interstitial lung diseases: knowns and unknowns.

Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S.

Eur Respir Rev. 2019 Feb 27;28(151). pii: 180100. doi: 10.1183/16000617.0100-2018. Print 2019 Mar 31. Review.

2.

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.

Rol N, de Raaf MA, Sun XQ, Kuiper VP, da Silva Gonçalves Bos D, Happé C, Kurakula K, Dickhoff C, Thuillet R, Tu L, Guignabert C, Schalij I, Lodder K, Pan X, Herrmann FE, van Nieuw Amerongen GP, Koolwijk P, Vonk-Noordegraaf A, de Man FS, Wollin L, Goumans MJ, Szulcek R, Bogaard HJ.

Cardiovasc Res. 2019 Feb 1;115(2):432-439. doi: 10.1093/cvr/cvy186.

PMID:
30032282
3.

Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy.

Piñol-Jurado P, Suárez-Calvet X, Fernández-Simón E, Gallardo E, de la Oliva N, Martínez-Muriana A, Gómez-Gálvez P, Escudero LM, Pérez-Peiró M, Wollin L, de Luna N, Navarro X, Illa I, Díaz-Manera J.

Cell Death Dis. 2018 Jul 10;9(7):776. doi: 10.1038/s41419-018-0792-6.

4.

Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

Redente EF, Aguilar MA, Black BP, Edelman BL, Bahadur AN, Humphries SM, Lynch DA, Wollin L, Riches DWH.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L998-L1009. doi: 10.1152/ajplung.00304.2017. Epub 2018 Mar 15.

PMID:
29543042
5.

Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.

Epstein Shochet G, Wollin L, Shitrit D.

Respirology. 2018 Aug;23(8):756-763. doi: 10.1111/resp.13287. Epub 2018 Mar 12.

PMID:
29532550
6.

The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection.

von Suesskind-Schwendi M, Boxhammer E, Hirt SW, Schreml S, Schmid C, Wollin L, Lehle K.

Exp Lung Res. 2017 Aug - Sep;43(6-7):259-270. doi: 10.1080/01902148.2017.1354408. Epub 2017 Oct 16.

PMID:
29035589
7.

Therapeutic targets in idiopathic pulmonary fibrosis.

Kolb M, Bonella F, Wollin L.

Respir Med. 2017 Oct;131:49-57. doi: 10.1016/j.rmed.2017.07.062. Epub 2017 Aug 1. Review.

PMID:
28947042
8.

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.

Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, Harre U, Chen CW, Distler O, Schett G, Wollin L, Distler JHW.

Ann Rheum Dis. 2017 Nov;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823. Epub 2017 Aug 16.

PMID:
28814429
9.

Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.

Herrmann FE, Wollin L, Wirth J, Gantner F, Lämmle B, Wex E.

Br J Pharmacol. 2017 Nov;174(21):3848-3864. doi: 10.1111/bph.13982. Epub 2017 Sep 20.

10.

Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator.

De Ruysscher D, Granton PV, Lieuwes NG, van Hoof S, Wollin L, Weynand B, Dingemans AM, Verhaegen F, Dubois L.

Radiother Oncol. 2017 Sep;124(3):482-487. doi: 10.1016/j.radonc.2017.07.014. Epub 2017 Jul 31.

PMID:
28774597
11.

Effects of nintedanib on the microvascular architecture in a lung fibrosis model.

Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ, Kreuz S, Stiller D, Wollin L, Konerding MA.

Angiogenesis. 2017 Aug;20(3):359-372. doi: 10.1007/s10456-017-9543-z. Epub 2017 Mar 10.

PMID:
28283856
12.

Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis.

Gilhodes JC, Julé Y, Kreuz S, Stierstorfer B, Stiller D, Wollin L.

PLoS One. 2017 Jan 20;12(1):e0170561. doi: 10.1371/journal.pone.0170561. eCollection 2017.

13.

Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.

de Raaf MA, Herrmann FE, Schalij I, de Man FS, Vonk-Noordegraaf A, Guignabert C, Wollin L, Bogaard HJ.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H604-12. doi: 10.1152/ajpheart.00656.2015. Epub 2016 Jun 24.

14.

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Bonella F, Stowasser S, Wollin L.

Drug Des Devel Ther. 2015 Dec 14;9:6407-19. doi: 10.2147/DDDT.S76648. eCollection 2015. Review.

15.

Interpretation of data from studies of effects of nintedanib on surfactant protein-D expression in human lung epithelial cells.

Wollin L.

Pulm Pharmacol Ther. 2015 Aug;33:15-6. doi: 10.1016/j.pupt.2015.05.007. Epub 2015 May 29. No abstract available.

PMID:
26027552
16.

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.

Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, Distler JH.

Ann Rheum Dis. 2016 May;75(5):883-90. doi: 10.1136/annrheumdis-2014-207109. Epub 2015 Apr 9.

PMID:
25858641
17.

The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.

Wex E, Kollak I, Duechs MJ, Naline E, Wollin L, Devillier P.

Br J Pharmacol. 2015 Jul;172(14):3537-47. doi: 10.1111/bph.13143. Epub 2015 May 12.

18.

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M.

Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Review.

19.

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B.

J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi: 10.1124/jpet.113.208223. Epub 2014 Feb 20.

PMID:
24556663
20.

The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.

Schymeinsky J, Mayer H, Tomsic C, Tilp C, Schuetz JD, Cui Y, Wollin L, Gantner F, Erb KJ.

PLoS One. 2013 Apr 22;8(4):e61193. doi: 10.1371/journal.pone.0061193. Print 2013.

21.

Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo.

Wex E, Bouyssou T, Duechs MJ, Erb KJ, Gantner F, Sanderson MP, Schnapp A, Stierstorfer BE, Wollin L.

Eur J Immunol. 2011 Nov;41(11):3208-18. doi: 10.1002/eji.201141502. Epub 2011 Sep 26.

22.

Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD.

Wollin L, Pieper MP.

Pulm Pharmacol Ther. 2010 Aug;23(4):345-54. doi: 10.1016/j.pupt.2010.03.008. Epub 2010 Apr 1.

PMID:
20362689
23.

Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.

Hoymann HG, Wollin L, Muller M, Korolewitz R, Krug N, Braun A, Beume R.

Pharmacology. 2009;83(3):188-95. doi: 10.1159/000196814. Epub 2009 Jan 29.

PMID:
19176983
24.
25.

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.

Pulm Pharmacol Ther. 2006;19(5):343-52. Epub 2005 Oct 28.

PMID:
16257550
26.
27.

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.

Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G.

Am J Respir Crit Care Med. 2005 Oct 1;172(7):848-53. Epub 2005 Jun 16.

PMID:
15961691
28.

[Doula--a new concept in obstetrics].

Thomassen P, Lundwall M, Wiger E, Wollin L, Uvnäs-Moberg K.

Lakartidningen. 2003 Dec 18;100(51-52):4268-71. Swedish.

PMID:
14756088
29.

Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.

Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M, Webb DC, Foster PS.

J Pharmacol Exp Ther. 2003 Oct;307(1):349-55. Epub 2003 Sep 3.

PMID:
12954795
30.
31.

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.

J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

PMID:
11259555
32.
33.

Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice.

Stamme C, Bundschuh DS, Hartung T, Gebert U, Wollin L, Nüsing R, Wendel A, Uhlig S.

Infect Immun. 1999 Nov;67(11):5642-50.

34.

Functional and fine structural changes in isolated rat lungs challenged with endotoxin ex vivo and in vitro.

Uhlig S, Brasch F, Wollin L, Fehrenbach H, Richter J, Wendel A.

Am J Pathol. 1995 May;146(5):1235-47.

35.

Contributions of thromboxane and leukotrienes to PAF-induced impairment of lung function in the rat.

Uhlig S, Wollin L, Wendel A.

J Appl Physiol (1985). 1994 Jul;77(1):262-9.

PMID:
7961243
36.

An improved setup for the isolated perfused rat lung.

Uhlig S, Wollin L.

J Pharmacol Toxicol Methods. 1994 Apr;31(2):85-94.

PMID:
8032099
37.

Neurophysiologic and behavioral effects of certain anesthetics administered intramuscularly in the rhesus monkey (Macaca mulatta).

Hinko PJ, Wendt W, Wollin LR, Massopust LC Jr.

Am J Vet Res. 1970 Sep;31(9):1661-78. No abstract available.

PMID:
4990321

Supplemental Content

Loading ...
Support Center